PracticeVideosBlogFlashcardsEspañol
All Practice Exams

100+ Free FEBU Practice Questions

Pass your Fellow of the European Board of Urology exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
EBU states that the average success rate for the Part 1 Written Exam is 85%. Pass Rate
100+ Questions
100% Free
1 / 100
Question 1
Score: 0/0

A 68-year-old man presents with bothersome voiding and storage LUTS suggestive of benign prostatic obstruction. Which initial assessment is most appropriate in routine evaluation?

A
B
C
D
to track
Same family resources

Explore More European Specialty Medical Exams

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Certificate of Fellowship of the European Board of Nuclear Medicine

Practice Questions

EBP-EAP Examination in Paediatrics

Practice Questions

EBSQ Examination in General Surgery

Practice Questions

EFOG-EBCOG Part 1 Knowledge Based Assessment

Practice Questions

EFOG-EBCOG Part 2 Clinical Skills Assessment OSCE

Practice Questions

European Board Examination in Emergency Medicine

Practice Questions
2026 Statistics

Key Facts: FEBU Exam

2 parts

Part 1 Written Exam and Part 2 Oral Exam

https://www.ebu.com/examination/febu/

110

Part 1 single correct answer MCQs

https://www.ebu.com/examination/part-1-written-exam/

12 Nov 2026

2026 Part 1 Written Exam date

https://www.ebu.com/examination/part-1-written-exam/important-information-part-1/

4 cases

Part 2 oral cases

https://www.ebu.com/examination/part-2-oral-exam/

32 / 48

Part 2 passing score and maximum score

https://www.ebu.com/wp-content/uploads/2026/01/Part-2-Oral-Exam_Scoring-system.pdf

5 years

Maximum interval from Part 1 to Part 2

https://www.ebu.com/examination/febu/

5 years

FEBU title validity from 2025 onward

https://www.ebu.com/examination/febu/

~85%

Average Part 1 success rate stated by EBU

https://www.ebu.com/examination/part-1-written-exam/

For current planning on 5 June 2026, eu-ebusr-exam should be treated as FEBU, the Fellow of the European Board of Urology credential, not as a separate EBUSR title. Official facts include a two-part exam, 110 single correct answer MCQs in Part 1, no negative marking, cohort-based Part 1 standard setting, Part 1 2026 on 12 November 2026, a Part 2 oral exam with 4 cases lasting approximately 60 minutes, Part 2 passing score 32 of 48, maximum 5 years between Part 1 and Part 2, and 5-year FEBU title validity with revalidation from 2025.

Sample FEBU Practice Questions

Try these sample questions to test your FEBU exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A colleague is building a revision course and labels the credential as a separate urology registry title. Which correction best aligns with the official identity of the examination?
A.The credential is the European Basic Urology Specialty Registry certificate.
B.The credential is Fellow of the European Board of Urology (FEBU), awarded through the European Board Examinations in Urology.
C.The credential is a European clinical privileges document issued independently of national registration.
D.The credential is the EAU Guidelines certificate for urologic oncology.
Explanation: The official title is FEBU, obtained through the European Board Examinations in Urology. It is a mark of quality and CV asset, not a separate registry qualification or practice-rights document; practice rights remain governed by national authorities.
2Which candidate profile meets the standard eligibility route for FEBU exams in an EBU member-country pathway?
A.A second-year resident in an unofficial observership who plans to enter formal training later.
B.A certified physician in a non-urological specialty who has completed a urology rotation.
C.A medical student who has passed an EAU online course and has a supervisor letter.
D.A final-year resident in an official national urology training programme in an EBU member country, with training completed no later than October of the following year.
Explanation: FEBU participation is reserved to candidates trained or certified in an EBU member country, including final-year residents in official national urology training completed by the specified October deadline, or certified urologists with a national specialist diploma. Informal observerships, other specialties, or student status do not satisfy this route.
3Which statement correctly describes the FEBU Part 1 Written Exam format and scoring?
A.It consists of 110 single-correct-answer MCQs, is web-based on assessmentQ with online invigilation, has no negative marking, and uses cohort-based standard setting with the average score and standard deviation.
B.It consists of 80 extended-matching questions, is open-book, and the pass mark is a fixed 70 percent every year.
C.It is an oral viva with four cases and two examiners, with a passing score of 32 out of 48.
D.It releases item content after the examination for candidate review and challenge.
Explanation: Part 1 is a supervised web-based written exam with 110 single-correct-answer MCQs, no negative marking, and cohort-based standard setting. The oral four-case format and 32/48 passing score refer to Part 2, and the written exam content is not disclosed.
4A final-year resident preparing for the 2026 FEBU Part 1 Written Exam asks about timing, format and fees. Which information is correct?
A.It is held on 12 October 2026 from 09:00 to 12:00 CET, is oral, and fees are paid directly at the exam centre.
B.It is held over five days in March 2027 and may be taken at any time during a 24-hour window.
C.It is scheduled for 12 November 2026, 14:30-16:30 CET, as a closed-book web-based MCQ exam with online supervision; the listed 2026 fees are EUR 575 regular or EUR 525 reduced for eligible certified-programme residents.
D.It is a take-home essay exam with local society marking and no online supervision.
Explanation: The 2026 FEBU Part 1 Written Exam is listed for 12 November 2026 from 14:30 to 16:30 CET, closed-book, web-based, and supervised online, with EUR 575 regular and EUR 525 reduced fees. The five-day window describes the formative in-service assessment, not the high-stakes Part 1 exam.
5Which description best matches the FEBU Part 2 Oral Exam and related title rules?
A.It is a 110-question written test; the FEBU title is lifelong from 2025 onward without revalidation.
B.It is an unstructured portfolio interview; Part 1 remains valid indefinitely before Part 2.
C.It is a case-based oral exam using four cases assessed by two urologists over about 60 minutes; scoring includes diagnostic acumen, clinical judgement and therapy, with 32/48 as the oral passing score, and the Part 1-to-Part 2 interval may not exceed five years.
D.It is a surgical skills assessment that automatically overrides national registration rules.
Explanation: Part 2 is case-based, lasts about an hour, uses four cases and two urologists, and scores diagnostic acumen, judgement and therapy; 32/48 is the oral passing score. Part 1 must be followed by Part 2 within five years, and from 2025 the FEBU title is time-limited and requires CME-based revalidation rather than serving as a practice-rights document.
6A 63-year-old biopsy-naive man has a confirmed PSA of 7.4 ng/mL, normal urinalysis, benign DRE and life expectancy greater than 10 years. Multiparametric MRI shows a PI-RADS 4 lesion in the peripheral zone. What is the most appropriate next diagnostic step?
A.Perform prostate biopsy directed at the MRI lesion, usually combined with systematic sampling according to local protocol.
B.Begin androgen deprivation therapy because MRI is sufficient to diagnose clinically significant prostate cancer.
C.Repeat PSA annually without biopsy because a benign DRE excludes significant cancer.
D.Treat empirically with antibiotics for six weeks and avoid imaging-targeted biopsy.
Explanation: A suspicious MRI lesion in a biopsy-naive man with persistent PSA elevation should lead to biopsy, with targeted cores and commonly systematic sampling to reduce missed clinically significant disease. MRI is not a histologic diagnosis, a benign DRE does not exclude cancer, and empiric antibiotics are not a substitute without evidence of infection.
7A 66-year-old man is diagnosed with cT1c prostate adenocarcinoma, ISUP Grade Group 1, PSA 6.2 ng/mL, PSA density 0.09 ng/mL/cc, and two short positive cores. MRI shows no extracapsular extension. He is anxious about urinary and sexual adverse effects. Which initial management is most guideline-consistent?
A.Recommend immediate docetaxel plus androgen deprivation therapy.
B.Perform radical cystoprostatectomy because any prostate cancer requires organ removal.
C.Use lifelong androgen deprivation therapy alone as definitive treatment.
D.Offer active surveillance with structured PSA, clinical review, MRI and repeat biopsy strategy.
Explanation: This is low-risk localized prostate cancer in a man suitable for surveillance, so active surveillance is the standard initial approach. Docetaxel is for metastatic systemic treatment, cystoprostatectomy is a bladder cancer operation, and ADT alone is not appropriate definitive therapy for low-risk localized disease.
8A 69-year-old man has newly diagnosed prostate cancer with PSA 28 ng/mL, cT2c disease, and biopsy ISUP Grade Group 2. He has no symptoms of metastasis. Which statement about risk grouping and staging is most appropriate?
A.He is low risk because Grade Group 2 is not high grade.
B.He meets high-risk criteria because PSA is greater than 20 ng/mL and cT2c disease is present; metastatic staging should be performed before definitive local treatment.
C.He requires no staging imaging because symptoms are absent.
D.He should be managed with antibiotics and repeat PSA only.
Explanation: High-risk prostate cancer can be defined by PSA greater than 20 ng/mL, high clinical stage, or high grade; this patient meets high-risk criteria through PSA and cT2c stage. Absence of symptoms does not remove the need for staging, and antibiotics or low-risk surveillance logic would under-stage and under-treat him.
9A fit 71-year-old man has cT3aN0M0 prostate cancer, ISUP Grade Group 4, PSA 17 ng/mL and negative staging for distant metastases. What is the most appropriate counselling?
A.Active surveillance is preferred because the PSA is below 20 ng/mL.
B.Offer definitive local treatment with curative intent, such as external beam radiotherapy plus long-term androgen deprivation therapy or radical prostatectomy in a multimodal strategy.
C.Treat with transurethral resection of the prostate alone to remove the tumour.
D.Use bicalutamide monotherapy and omit local therapy because the disease is locally advanced.
Explanation: cT3a and Grade Group 4 disease is high-risk or locally advanced prostate cancer requiring curative-intent multimodal counselling when staging is negative. Surveillance and TURP alone are inadequate, and non-castrating antiandrogen monotherapy without local treatment is not a standard curative approach.
10A 64-year-old man presents with de novo metastatic hormone-sensitive prostate cancer with multiple bone metastases, good performance status and no major contraindication to systemic therapy. Which principle should guide first-line treatment?
A.Observation alone until skeletal-related events develop.
B.Radical prostatectomy alone because systemic therapy is unnecessary in metastatic disease.
C.Single-agent antibiotic therapy should be tried before any cancer-directed treatment.
D.Androgen deprivation therapy should be intensified with an androgen receptor pathway inhibitor, and triplet therapy with docetaxel may be considered in selected fit patients with high-volume disease.
Explanation: Fit patients with metastatic hormone-sensitive prostate cancer generally benefit from treatment intensification beyond ADT alone, using an androgen receptor pathway inhibitor and, in selected high-volume fit patients, docetaxel-based triplet therapy. Observation, surgery alone and antibiotics do not address systemic metastatic prostate cancer.

About the FEBU Exam

FEBU is the Fellow of the European Board of Urology credential. Candidates must pass the Part 1 Written Exam and Part 2 Oral Exam to receive the FEBU diploma and title. EBU describes the title as a mark of quality and added qualification; it is not a licence to practise urology.

Assessment

The European Board Examinations in Urology consist of Part 1 Written Exam and Part 2 Oral Exam. Part 1 covers the full range of urological topics including basic science through 110 single correct answer MCQs. Part 2 evaluates common everyday urology cases through a case-based oral examination with two urologist examiners.

Time Limit

Part 1 2026 is scheduled for 12 November 2026 from 14:30 to 16:30 Central European Time. Part 2 is approximately 60 minutes; the 2026 listed sitting is Saturday 20 June 2026 from 09:00 to 18:00 in Leuven, Belgium, with individual session assignments communicated to candidates.

Passing Score

Part 1 uses cohort-based standard setting based on average score and standard deviation, with no negative marking and undisclosed question content. Part 2 has 4 cases scored on diagnostic acumen, clinical judgement, and therapy, with maximum score 48 and passing score 32.

Exam Fee

Part 1 Written Exam 2026: EUR 575 regular fee, or EUR 525 reduced fee for residents trained at an EBU Certified Residency Training Programme in Urology. Part 2 Oral Exam 2026: EUR 650 registration fee. (European Board of Urology)

FEBU Exam Content Outline

Format

Part 1 Written and Part 2 Oral

110 single correct answer MCQs in the web-based Part 1 Written Exam and 4 common-practice cases in the Part 2 Oral Exam.

Eligibility

EBU Member-Country Training or Certification

Final-year residents in official EBU member-country urology training and certified urologists with a national urology specialist diploma.

Clinical

Core Urology Knowledge

Oncology, stones, infection, endourology, LUTS, neuro-urology, incontinence, andrology, infertility, paediatrics, reconstruction, emergencies, and trauma.

Oral readiness

Everyday Case Management

Structured evaluation, diagnostic acumen, clinical judgement, therapy planning, communication, consent, perioperative risk, complication management, and MDT reasoning.

Professional

Certification, Integrity, and Revalidation

No licence-to-practise status, exam confidentiality, sequestering policy, 5-year Part 1-to-Part 2 interval, and 5-year FEBU title validity from 2025.

How to Pass the FEBU Exam

What You Need to Know

  • Passing score: Part 1 uses cohort-based standard setting based on average score and standard deviation, with no negative marking and undisclosed question content. Part 2 has 4 cases scored on diagnostic acumen, clinical judgement, and therapy, with maximum score 48 and passing score 32.
  • Assessment: The European Board Examinations in Urology consist of Part 1 Written Exam and Part 2 Oral Exam. Part 1 covers the full range of urological topics including basic science through 110 single correct answer MCQs. Part 2 evaluates common everyday urology cases through a case-based oral examination with two urologist examiners.
  • Time limit: Part 1 2026 is scheduled for 12 November 2026 from 14:30 to 16:30 Central European Time. Part 2 is approximately 60 minutes; the 2026 listed sitting is Saturday 20 June 2026 from 09:00 to 18:00 in Leuven, Belgium, with individual session assignments communicated to candidates.
  • Exam fee: Part 1 Written Exam 2026: EUR 575 regular fee, or EUR 525 reduced fee for residents trained at an EBU Certified Residency Training Programme in Urology. Part 2 Oral Exam 2026: EUR 650 registration fee.

Keys to Passing

  • Complete 500+ practice questions
  • Score 80%+ consistently before scheduling
  • Focus on highest-weighted sections
  • Use our AI tutor for tough concepts

FEBU Study Tips from Top Performers

1Use the EAU guidelines and current major urology texts for broad Part 1 coverage across oncology, stones, LUTS, infection, functional urology, paediatrics, reconstruction, emergencies, and basic science.
2Practise single-correct-answer reasoning: identify the most appropriate next diagnostic or management step, not every potentially reasonable option.
3For Part 2, rehearse a concise oral structure: problem representation, immediate risks, investigations, differential, management plan, complications, and follow-up.
4Keep exam logistics straight: Part 1 has 110 SCA MCQs, no negative marking, and cohort-based standard setting; Part 2 has 4 cases and a 32-of-48 passing score.
5Avoid treating FEBU as licensure; frame it correctly as a European mark of quality and additional qualification that requires revalidation from 2025 onward.

Frequently Asked Questions

What is the official current identity for this exam ID?

The official current EBU pages identify the credential as Fellow of the European Board of Urology, abbreviated FEBU. This page uses eu-ebusr-exam as the site exam ID but does not treat EBUSR as a separate official title.

What is the FEBU Part 1 format?

The FEBU Part 1 Written Exam consists of 110 single correct answer MCQs covering the full range of urology, including basic science. It is web-based, closed book, and remotely supervised through assessmentQ.

What is the FEBU Part 2 format?

The FEBU Part 2 Oral Exam evaluates 4 common urology cases. A team of two urologists examines each candidate, and the session lasts approximately 60 minutes.

How is FEBU Part 1 scored?

EBU applies cohort-based standard setting using the average score and standard deviation. There is no negative marking, and question content is not disclosed.

How is FEBU Part 2 scored?

Part 2 scores diagnostic acumen, clinical judgement, and therapy across 4 cases. The maximum score is 48 and the passing score is 32.

Does FEBU grant the right to practise urology?

No. EBU states that FEBU is a mark of quality and an added qualification, but it does not grant rights and is not a licence to practise urology.